The antibody-mediated rejection market comprises products such as inhibition of co-stimulation pathways, Inhibition of complement activation, Inhibition of apoptosis signaling, and Non-depleting anti-CD4 monoclonal antibodies. These products are used for treating solid organ transplant recipients that experience organ rejection due to presence of preformed donor-specific HLA antibodies.
The Global Antibody-mediated Rejection Market is estimated to be valued at US$ 126.5 Mn in 2024 and is expected to exhibit a CAGR of 12 % over the forecast period 2024-2031.
Key Takeaways
Key players operating in the antibody-mediated rejection market are CSL Behring,Hansa Biopharma AB,Viela Bio,Janssen Biotech, and Pfizer . CSL Behring is a major player that offers products such as Privigen and Hizentra for treatment of chronic inflammatory demyelinating polyneuropathy. Hansa Biopharma's lead asset, imlifidase enables access to lifesaving transplants by eliminating HLA antibodies so that highly sensitized patients can receive a transplants. Viela Bio offers enabolic to deplete alloreactive B cells in highly sensitized patients to prevent antibody-mediated rejection after organ transplantation.
The growing incidence of chronic kidney disease, liver disease, and other organ failures has resulted in a substantial rise in the number of organ transplant procedures performed worldwide. This is a major factor fueling the demand for effective therapeutic products to minimize the risk of rejection. According to the Global Observatory on Donation and Transplantation, over 140,000 solid organ transplant procedures were performed globally in 2020, registering a year-over-year growth of 4%.
Key players are actively expanding their geographic presence and product portfolios through strategic acquisitions and partnerships. For instance, in 2019 Pfizer acquired Therachon to strengthen its pipeline of investigational therapies for rare diseases including antibody-mediated rejection. Several key pharma companies are also investing in R&D for novel biologic therapies with improved safety profiles and long-term efficacy.
Market key trends
The key trend gaining traction in the AMR market is the rising focus on developing novel therapies based on advanced modalities like gene therapy, cell therapy and regenerative medicine. Companies are exploring innovative mechanisms such as ex-vivo gene modification of stem cells to make donor organs devoid of antigens incompatible to recipient’s immune system. This could vastly reduce dependence on lifelong immunosuppression regimens and their associated side effects. Significant funds are being directed towards clinical research on conditioning regimens that promote immune tolerance after organ transplant through gene-edited stem cells or tissues.
Porter’s Analysis
Threat of new entrants: Regulatory processes for pharmaceutical industry pose high entry barriers.
Bargaining power of buyers: Large healthcare providers enjoy more negotiation power over pricing.
Bargaining power of suppliers: Few large CROs/CMOs strengthen suppliers' bargaining position.
Threat of new substitutes: Limited substitutes available due to specificity of humanized monoclonal antibodies in transplantation.
Competitive rivalry: Intense competition between established players to develop advanced therapies.
Geographical Regions
North America accounts for the largest share of the global antibody-mediated rejection market, primarily due to rising organ transplantation procedures in the US and early adoption of advanced therapies. Increasing incidence of chronic diseases causing organ failures also propels the regional market growth.
Asia Pacific exhibits the fastest growth for antibody-mediated rejection market over the forecast period. Rapidly developing healthcare infrastructure, rising healthcare spending, growing patient awareness about availability of advanced treatment options, and increasing organ transplantation surgeries are some key factors fueling the APAC market expansion. China and India represent major revenue pockets attributed to their huge population base suffering from chronic conditions.
The antibody-mediated rejection market witnesses notable concentration in developed regions like North America and Western Europe owing to concentrated presence of leading industry players, higher acceptance of premium therapies, and strong reimbursement framework. However, emerging Asian and Latin American countries present enticing opportunities for market participants to leverage unmet needs.
What Are The Key Data Covered In This Antibody-mediated Rejection Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Antibody-mediated Rejection 's growth between 2024 and 2031.
:- Accurate calculation of the size of the Antibody-mediated Rejection and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Antibody-mediated Rejection Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Antibody-mediated Rejection vendors
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
